Farr Miller & Washington’s Moderna MRNA Stock Holding History

Farr Miller & Washington’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$249K	Buy	+646	New	+$238K	0.02%	168

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Farr Miller & Washington's MRNA Position: Q3 2021 in Review

Farr Miller & Washington opened a new position in Moderna (MRNA) in Q3 2021: 646 shares worth $249K. The stake represents 0.02% of the portfolio and ranks #168 among its holdings.

1,140 funds tracked by Wall St. Rank hold MRNA as of Q3 2021.

Farr Miller & Washington held 646 shares of Moderna worth $249K as of Q3 2021.
Moderna was a new Farr Miller & Washington position in Q3 2021.
Moderna made up 0.02% of Farr Miller & Washington's portfolio in Q3 2021, its #168 holding.
1,140 funds tracked by Wall St. Rank held Moderna as of Q3 2021.

Based on Farr Miller & Washington's 13F filing for Q3 2021, filed 15 Nov 2021.